被美列入UVL 藥明生物(2269.HK)再度跌超6% 3日內累跌近30%
格隆匯2月10日丨藥明生物今日繼續下跌,盤中一度跌超8%至56.55港元,目前跌6.4%報57.6港元,市值2430億港元。美商務部將藥明生物兩家子公司(無錫藥明生物技術股份和上海藥明生物技術)列入未經核實名單(UVL),藥明生物2月8日當天盤中暴跌近23%後臨時停牌,2月9日復牌後再度收跌1%,今日跌勢繼續,3日內已累跌近30%。藥明系的另一隻股票藥明康德H股近3日內也累跌超20%,A股最近3日累跌約17%。列入未經核實名單將限制從美國進口某些生物反應器硬件和超濾器,藥明生物管理層表示正在與美國商務部積極溝通,希望在未來幾個月內完成檢查並退出名單。藥明生物子公司被列入UVL,機構普遍認為影響可控。摩通稱對其運營和財務的影響在短期內是可控的,而且藥明生物的供應商多元化戰略似乎具有先見之明,亦有提出上訴的途徑和與供應一同解決問題。富瑞指出,被列入UVL可能是由於採購物料最終用途審查未得到滿足,若公司進行了更正,包括提交的書面證據,則可以將公司從UVL中剔除。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.